

**BEFORE THE UNITED STATES JUDICIAL PANEL  
ON MULTIDISTRICT LITIGATION**

IN RE: INVOKANA (CANAGLIFLOZIN)  
PRODUCTS LIABILITY LITIGATION

MDL Docket No. 2750

**DEFENDANT JANSSEN PHARMACEUTICALS, INC.’S  
RESPONSE TO MOTION FOR TRANSFER AND COORDINATION AND  
CONSOLIDATED PRETRIAL PROCEEDINGS**

Defendant Janssen Pharmaceuticals, Inc. (“Janssen”) agrees with movants that there are cases pending in federal courts across the country involving Invokana that should be consolidated and transferred pursuant to 28 U.S.C. § 1407 to a single district court for coordinated pretrial proceedings. Given the growing trend in recent years, however, for the formation of multidistrict litigation to result in the filing of meritless claims to increase plaintiff inventories and to encourage resolution, these cases need to be consolidated and transferred to a judge with not only the skill and knowledge to efficiently and effectively manage the coordinated proceedings, but also the willingness and motivation to rein in any abuses that may result from coordination. Janssen agrees with movants that Judge Brian Martinotti of the District of New Jersey is an appropriate choice for transferee judge. In the alternative, Janssen proposes Judge Amy St. Eve of the Northern District of Illinois.

**I. BACKGROUND**

There are currently at least 57<sup>1</sup> actions pending in 11 different federal judicial districts asserting common factual allegations and involving overlapping claims and legal issues.

---

<sup>1</sup> Movants’ Amended Schedule of Actions included 55 actions in 11 judicial districts. The Schedule failed to include two actions of which Janssen is aware—*Green v. Janssen*

**A. Plaintiffs And Their Basic Allegations.**

Plaintiffs in this litigation allege injuries arising from their use of Invokana,<sup>2</sup> a prescription drug developed by and manufactured for Janssen. The Food and Drug Administration (“FDA”) approved Invokana in 2013 as an adjunct to diet and exercise to help lower blood sugar in adults with type 2 diabetes. Invokana is a member of a class of pharmaceuticals known as sodium-glucose cotransporter 2 (“SGLT2”) inhibitors, which are designed to inhibit renal glucose reabsorption with the goal of lowering blood glucose. Invokana was the first SGLT2 inhibitor approved for use by the FDA.

Plaintiffs contend that they have experienced injuries including, but not limited to, kidney failure and ketoacidosis as a result of ingesting Invokana, which they allege was defectively designed, manufactured, and/or marketed by Janssen. Plaintiffs all allege that Janssen failed to provide adequate warnings of the risks and dangers posed by Invokana.

**B. Janssen Is The Only Common Defendant Across All Cases.**

While there are a number of co-defendants named in the pending actions,<sup>3</sup> Janssen is the

---

*Pharmaceuticals, Inc. et al.*, Case No. 3:16-cv-6046 (D.N.J.) and *Moore v. Janssen Pharmaceuticals, Inc. et al.*, Case No. 0:16-cv-00065 (E.D. Ky.). Of the cases listed in movants’ Amended Schedule of Actions, Janssen has been served in only 30. (*See* Doc. 23-2 (Schedule of Actions for Notice of Appearance for John Q. Lewis, counsel for Janssen).)

<sup>2</sup> In one case listed on Movants’ Amended Schedule of Action, *House v. Janssen Pharmaceuticals, Inc. et al.*, Case No. 3:15cv-894 (W.D. Ky.), plaintiff alleges use of Invokana, Invokamet, and Farxiga. Invokamet is a combination of Invokana and metformin, and was developed by and is manufactured for Janssen. Farxiga, also a SGLT2 inhibitor, is a product of Bristol-Meyers Squibb and AstraZeneca. (*See House* Compl. ¶ 34.)

<sup>3</sup> The following defendants have been variously named in the 30 cases in which Janssen has been served: Johnson & Johnson, Janssen Research & Development, LLC, Janssen Ortho, LLC, and Mitsubishi Tanabe Pharma Corporation. Johnson & Johnson is a New Jersey corporation with its principal place of business in New Jersey. Janssen Research & Development, LLC (“JRD”), is a New Jersey limited liability company with its principal place of business in New Jersey. Janssen Ortho, LLC, is a Delaware limited liability company with its principal place of business in Puerto Rico. Mitsubishi Tanabe Pharma Corporation is a Japanese corporation with its principal place of business in Osaka, Japan.

only defendant named in all of these cases—which makes sense. Invokana was developed by and is manufactured for Janssen, and Janssen holds the New Drug Application (NDA) for Invokana. Janssen is a Pennsylvania corporation with its principal place of business in Titusville, New Jersey. The Janssen teams responsible for clinical research and development, medical affairs, regulatory approvals and compliance, labeling, marketing and sales of Invokana are based in New Jersey, and individuals with substantive knowledge and decision-making authority regarding the development, labeling, regulatory compliance, marketing, and sale of Invokana in the United States who would be potential trial witnesses are located in New Jersey.

**C. The Location And Status Of The Pending Actions.**

Of the at least 57 Invokana cases that are currently pending, none has advanced significantly through discovery, nor toward trial, such that transfer would be unduly prejudicial or inefficient. Indeed, Janssen has only been served in 32 of the 57 cases. Of these, answers have been filed in only six cases. In the remaining 26 cases, motions to dismiss are awaiting disposition or dispositive motion briefing is in progress.<sup>4</sup> There have been several rulings on important legal issues in these cases.<sup>5</sup>

---

<sup>4</sup> Three of the earliest-filed Invokana cases—*Counts v. Janssen Pharmaceuticals, Inc., et al.*, Case No. 3:15-01196 (S.D. Ill.), *Allen v. Janssen Pharmaceuticals, Inc., et al.*, Case No. 3:15-01195 (S.D. Ill.), and *Schurman v. Janssen Pharmaceuticals, Inc., et al.*, Case No. 3:15-01180 (S.D. Ill.)—are all pending before Judge Staci Yandle in the Southern District of Illinois. That district is known to be overburdened, ranking 94th out of 94 district courts in terms of time from filing to resolution of civil cases, with nearly 40% of its cases pending for over three years. See <http://www.uscourts.gov/statistics/table/na/federal-court-management-statistics/2016/06/30-1> (last visited Oct. 6, 2016). This is reflected in the management of *Counts*, *Allen*, and *Schurman*; a motion to dismiss in each case has been fully briefed and pending disposition since late January or early February of this year.

<sup>5</sup> The courts that have ruled on dispositive motions have entered orders addressing lack of personal jurisdiction over Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, and other Defendants, preemption of design defect and failure-to-warn claims, and the insufficiency of Plaintiffs' pleadings.

## II. ARGUMENT

### A. Transfer And Consolidation Of Most Invokana Actions Is Appropriate.

While Janssen disagrees with Plaintiffs' characterization of the facts, it agrees that there are common issues meeting the standards for pretrial consolidation. Of course, these cases all involve very individualized and plaintiff-specific issues, including different usage histories,

---

For example, in *Fleming v. Janssen Pharmaceuticals, Inc.*, No. 2:15-cv-02799, --- F. Supp. 3d ---, 2016 WL 3180299 (W.D. Tenn. May 6, 2016), the court granted Johnson & Johnson's motion to dismiss for lack of personal jurisdiction, holding that plaintiff's allegations were insufficient to establish purposeful availment in Tennessee. *See id.* at \*1-\*3. In addition to finding no purposeful availment, the court also held that the plaintiff did not demonstrate that his alleged injuries arose from Johnson & Johnson's purported forum activities. *See id.* at \*4. The court also dismissed plaintiff's design claims with prejudice on the grounds that they were preempted. *See Fleming*, 2016 WL 3180299, at \*4-\*5 (confirming that "preemption can apply to both generic and branded drugs" and "Defendants could not comply with both state and federal law with respect to Invokana"). *Fleming* subsequently was voluntarily dismissed.

In *Brazil v. Janssen Research & Dev. LLC*, --- F. Supp. 3d ---, 2016 WL 4844442, at \*7 (N.D. Ga. Mar. 24, 2016), the court dismissed Johnson & Johnson for lack of personal jurisdiction on the grounds that it is a holding company that was not involved in the manufacture or sale of Invokana. The court also dismissed all of the plaintiff's claims as insufficiently pled. *See id.* at \*8-\*11. In *Brazil v. Janssen Research & Development LLC*, No. 4:15-cv-0204, --- F. Supp. 3d ---, 2016 WL 3748771 (N.D. Ga. July 11, 2016), the court then considered the plaintiff's amended complaint and dismissed the manufacturing defect claim, design defect claims, and violation of consumer protection law claim for lack of pleading specificity. *Id.* at \*5-\*6, \*8-\*9. The court also found the design defect claims to be preempted to the extent they were based on an alleged failure to change to chemical composition of the drug. *See id.* at \*43. Finally, the court dismissed the failure-to-warn claims against Janssen Ortho, LLC as preempted because it was not the NDA holder and thus had no authority to change the labeling of Invokana. *Id.* at \*47-\*50. Johnson & Johnson was dismissed on this same basis after the plaintiff conceded the issue in *Lessard v. Janssen Pharmaceuticals, Inc.*, No. 16-CV-2329 (E.D. La.).

In another Invokana case, the Southern District of Alabama dismissed the plaintiff's complaint as a "shotgun pleading" and then specifically cautioned that "plaintiff should seriously consider not only the defendants' briefing regarding preemption but, as well, how the courts are 'coming down' on this issue." Order at 3 n.3, *Collie v. Janssen Research & Dev., LLC*, No. CA 15-0636-KD-C (S.D. Ala. July 29, 2016). *Collie* subsequently was voluntarily dismissed.

Finally, the court in *Guidry v. Janssen Pharmaceuticals, Inc. et al.*, No. 15-4591, 2016 WL 4508342 (E.D. La. Aug. 29, 2016) granted a motion to dismiss for lack of personal jurisdiction filed by Mitsubishi Tanabe Pharma Corporation and Mitsubishi Tanabe America Development, Inc. *See id.* at \*4. That court also found the plaintiff's design defect claims preempted to the extent based on an alleged failure to adopt a safer alternative design after FDA approval, but it allowed the claims to survive under Louisiana law to the extent based on an alleged failure to adopt a safer alternative design before FDA approval. *See id.* at \*14.

different prescribing physicians, and different alleged injuries. But the cases also present overlapping factual allegations regarding the alleged risks associated with the use of Invokana and/or Invokamet and would thus benefit from coordinated pretrial proceedings.

Although Janssen acknowledges that there are benefits to be achieved through consolidation, Janssen also recognizes the potential pitfalls of multidistrict litigation. Creating a multidistrict proceeding can encourage the filing of claims of questionable merit and allow those claims to avoid the judicial scrutiny that they otherwise would receive if filed individually. As Judge Clay Land, transferee judge overseeing *In re Mentor Corp. ObTape Transobturator Sling Products Liability Litigation*, recently observed, “the evolution of the [multidistrict litigation] process toward providing an alternative dispute resolution forum for global settlements has produced incentives for the filing of cases that otherwise would not be filed if they had to stand on their own merit as a stand-alone action.” *In re Mentor Corp. ObTape Transobturator Sling Prods. Liab. Litig.*, MDL Doc. No. 2004, 4:08-md-2004, 2016 WL 4705827, at \*1 (M.D. Ga. Sept. 7, 2016). This results in a multidistrict proceeding—established for the purpose of managing cases efficiently to achieve judicial economy—“becom[ing] populated with non-meritorious cases that must nevertheless be managed by the transferee judge.” *Id.* To avoid these pitfalls, Janssen requests that the Panel consider the following when determining which cases to consolidate and where to transfer and consolidate those cases.

First, Janssen believes that cases naming only Invokana and/or Invokamet should be consolidated for coordinated pretrial proceedings. This Panel has indicated that it is “typically hesitant to centralize litigation against multiple, competing defendants which marketed, manufactured and sold [allegedly] similar products.” *In re: Yellow Brass Plumbing Component Prods. Liab. Litig.*, 844 F. Supp. 2d 1377, 1378 (J.P.M.L. 2012). This is often because “the

individual issues that result from the differences among each defendant's [product] with respect to product design, development, testing, warnings, and marketing will predominate over the common issues." *In re Power Morcellator Prods. Liab. Litig.*, 140 F. Supp. 3d 1351, 1353-54 (J.P.M.L. 2015). Here, Invokana and Invokamet belong to a class of pharmaceuticals that, in the United States, include four other single-use and combination prescription medicines marketed and distributed by other companies.<sup>6</sup> Each of these medicines have different labels, prescribing information, and regulatory histories. Any potential efficiencies to be gained through consolidation would be lost when having to contend with discovery involving these multiple products and multiple defendants. Accordingly, Janssen does not believe it would be appropriate to include cases involving claims regarding the other SGLT2 inhibitors among those cases to be consolidated.<sup>7</sup>

Second, when choosing an appropriate transferee judge, it is critical to identify a judge with the knowledge, skill, and experience in the efficient management of complex cases. A potential transferee judge also should demonstrate the willingness and motivation to actively manage the cases and swiftly address issues to ensure that the benefits of consolidation are achieved. A transferee judge also should be willing "to consider approaches that weed out non-meritorious cases early, efficiently and justly." *In re Mentor Corp. ObTape Transobturator Sling Prods. Liab. Litig.*, 2016 WL 4705827, at \*2.

---

<sup>6</sup> In addition to Invokana and Invokamet, SGLT2 inhibitors include Farxiga and Xigduo XR, distributed by AstraZeneca Pharmaceuticals LP; and Jardiance and Glyxambi, marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

<sup>7</sup> Applying this principle to the movants' Amended Schedule of Actions, *House*—a case involving Invokana/Invokamet and Farxiga—should not be included in the consolidation and transfer.

**B. The District Of New Jersey Is A Suitable Forum For The Multidistrict Litigation.**

Janssen agrees with movants that the District of New Jersey is an appropriate forum for transfer and consolidation of the Invokana cases for pretrial proceedings<sup>8</sup> before Judge Brian Martinotti.<sup>9</sup>

The District of New Jersey generally and Judge Martinotti specifically have significant experience handling multidistrict litigation involving pharmaceutical and medical device products liability actions. The District of New Jersey has been named the transferee district for multidistrict litigation multiple times, including most recently for the *In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation*. See Order, *In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, & Prods. Liab. Litig.*, MDL No. 2738, Doc. 134 (J.P.M.L. Oct. 4, 2016) (“Talc Transfer Order”); see generally, e.g., *In re Vytarin/Zetia Mktg., Sales Practices & Prods. Liab. Litig.*, 543 F. Supp. 2d 1378 (J.P.M.L. 2008); *In re: Zimmer Durom Hip Cup Prods. Liab. Litig.*, 717 F. Supp. 2d 1376 (J.P.M.L. 2010); *In re: Fosamax (Alendronate Sodium) Prods. Liab. Litig. (No. II)*, 787 F. Supp. 2d 1355 (J.P.M.L. 2011); *In re Plavix Mktg., Sales Practices & Prods. Liab. Litig. (No. II)*, 923 F. Supp. 2d 1376 (J.P.M.L. 2013); *In re: Benicar (Olmesartan) Prods. Liab. Litig.*, 96 F. Supp. 3d 1381 (J.P.M.L. 2015). Likewise Judge Brian Martinotti, while relatively new to the federal

---

<sup>8</sup> While Janssen agrees with the transfer and consolidation of these cases for pretrial purposes, it believes the transferor courts are likely the better forums for trial.

<sup>9</sup> When faced with infighting among plaintiffs over forum selection, the Panel has selected the forum where the majority of cases is pending—especially when defendants and some plaintiffs agree with that forum choice. See, e.g., *In re: Transitions Lenses Antitrust Litig.*, 730 F. Supp. 2d 1381, 1382 (J.P.M.L. 2010) (choosing Middle District of Florida as the transferee forum, in part because “[a]ll domestic defendants and plaintiffs in a majority of the actions support transfer to this district as a first or alternative choice”); *In re Auto. Refinishing Paint Antitrust Litig.*, 177 F. Supp. 2d 1378, 1379 (J.P.M.L. 2001) (noting “at least some plaintiffs and all domestic defendants support centralization” in the chosen district).

bench, has extensive experience handling large and complex pharmaceutical MDLs while he was on the state bench in New Jersey.<sup>10</sup> Indeed, he was one of three judges in New Jersey designated to handle consolidated litigation and routinely handled multiple state coordinated proceedings at one time.<sup>11</sup> *See, e.g.,* Case Mgmt. Order, *In re: Nuvaring Litig.*, No. BER-L-3081-09 (N.J. Super. Ct. Sept. 18, 2009); Case Mgmt. Order, *In re: Zelnorm Litig.*, No. BER-L-280-09 (N.J. Super. Ct. Sept. 14, 2009); Case Mgmt. Order, *In re Yaz, Yasmin, Ocella Litig.*, No. BER-L-3572-10 (Apr. 26, 2010); Case Mgmt. Order, *In re DePuy ASR Hip Implants Litig.*, No. BER-L-3971-11 (May 10, 2011); Case Mgmt. Order, *In re Stryker Rejuvenate & ABG II Hip Implant Litig.*, No. BER-L-936-13 (Feb. 20, 2013); Case Mgmt. Order, *In re Mirena Litig.*, No. BER-L-4098-13 (July 1, 2013); Notice to the Bar: Multicounty Litigation Reassignment—Pelvic Mesh (N.J. Oct. 31, 2014), *available at* <http://judiciary.state.nj.us/notices/2014/n141105b.pdf> (last visited Oct. 12, 2016).

Janssen believes that Judge Martinotti exhibits the attributes required for a transferee judge. Judge Martinotti has already brought his significant case management skills to bear in the

---

<sup>10</sup> In fact, Judge Martinotti has published an in-depth discussion of complex litigation in the New Jersey and federal court systems. *See* Hon. Brian R. Martinotti, J.S.C., *Complex Litigation in New Jersey and Federal Courts: An Overview of the Current State of Affairs and a Glimpse of What Lies Ahead*, 44 Loy. U. Chi. L.J. 561 (2012) (attached as Ex. A).

<sup>11</sup> The judge with the next most Invokana cases (four)—Judge Staci Yandle of the Southern District of Illinois—does not have similar experience handling consolidated litigation. And she at one time worked with Roger Denton, one of the lead counsel for Plaintiffs in the cases pending in that court. *Compare Staci Michelle Yandle '87 Confirmed to the U.S. District Court for the Southern District of Illinois*, Vanderbilt Law School, <http://law.vanderbilt.edu/news/staci-michelle-yandle-87-nominated-to-serve-on-the-u-s-district-court-for-the-southern-district-of-illinois/> (last visited Sept. 27, 2016) (explaining that Yandle worked at the law firm of Carr Korein Schlichter Kunin Montroy Glass & Bogard from 1987 until 2003), *with Williams v. Fischer*, 581 N.E.2d 744 (Ill. Ct. App. 1991) (listing Roger Denton of the law firm Carr Korein Tillery Kunin Montroy Glass & Bogard as attorney for Plaintiff-Appellant in 1991). While that may not give rise to disqualification or recusal, it does merit consideration as this Panel makes its selection.



cases pending before him. Within weeks of having Invokana cases assigned to him, Judge Martinotti scheduled a status conference on August 29, 2016, at which he directed counsel to meet and confer on, among other things, a short form complaint, short form answer, Plaintiff and Defendant fact sheets, and various discovery orders. (*See* Doc. 21, Case No. 3:16-cv-02386.) The parties recently appeared before Judge Martinotti again on October 5, 2016 to inform him of their progress. No other judge has advanced the pending Invokana cases in such a manner. Judge Martinotti has demonstrated his willingness and motivation to justly and efficiently manage this litigation based on both his past experience and current actions in the cases already on his docket, and he should be given the opportunity to manage the multidistrict litigation.

The District of New Jersey is a good choice for transferee forum for several additional reasons.

First, it currently has the largest number of pending cases—37 of the 57—far exceeding the next closest district by nearly tenfold. This is often a factor that the Panel considers when choosing a transferee forum. *See, e.g., In re Med. Informatics Eng'g, Inc., Customer Data Sec. Breach Litig.*, 148 F. Supp. 3d 1381, 1382 (J.P.M.L. 2015) (noting that the transferee forum contained a majority of the actions in dispute); *In re Air Crash Near Athens, Greece, on Aug. 14, 2005*, 435 F. Supp. 2d 1340, 1342 (J.P.M.L. 2007) (same); *In re Carbon Black Antitrust Litig.*, 277 F. Supp. 2d 1380, 1381 (J.P.M.L. 2003) (same); *In re Unumprovident Corp. Secs., Derivative & "ERISA" Litig.*, 280 F. Supp. 2d 1377, 1380 (J.P.M.L. 2003) (same); *In re High Pressure Laminate Antitrust Litig.*, No. 1368, 2000 WL 33180479, at \*1 (J.P.M.L. Oct. 6, 2000) (same). And all of the actions in the District of New Jersey are already pending before Judge Martinotti, which makes him a likely choice as transferee judge. *See, e.g., In re Packaged Seafood Prods. Antitrust Litig.*, 148 F. Supp. 3d 1375, 1377 (J.P.M.L. 2015) (selecting Southern

District of California and Judge Sammartino for coordinated proceedings because “[t]he vast majority of the related actions already are pending in this district, most before Judge Janis L. Sammartino, who has related the cases before her”); *In re: Online DVD Rental Antitrust Litig.*, 609 F. Supp. 2d 1376, 1377 (J.P.M.L. 2009) (choosing Judge Hamilton because the “vast majority of the actions” were already pending before her).

Second, the District of New Jersey is a convenient forum given that Janssen maintains its headquarters there. The Janssen teams responsible for clinical research and development, medical affairs, regulatory approvals and compliance, labeling, marketing and sales of Invokana are based in New Jersey, and individuals with substantive knowledge and decision-making authority regarding the development, labeling, regulatory compliance, marketing, and sale of Invokana in the United States who would be potential witnesses at trial are located in New Jersey. This is often a decisive factor when choosing a transferee forum. *See, e.g.*, Talc Transfer Order at 3; *In re Benicar (Olmesartan) Prods. Liab. Litig.*, 96 F. Supp. 3d 1381, 1383 (J.P.M.L. 2015) (selecting District of New Jersey for multidistrict proceedings because “defendants, are headquartered in that district, and thus many witnesses and relevant documents are likely to be found there”); *In re Cook Med., Inc., IVC Filters Mktg., Sales Practices & Prods. Liab. Litig.*, 53 F. Supp. 3d 1379, 1381 (J.P.M.L. 2014) (establishing MDL in Southern District of Indiana in part because “[defendant] Cook is headquartered in Indiana, where relevant documents and witnesses are likely to be found”).

Third, the District of New Jersey is geographically accessible to counsel and parties involved in this litigation, making it a good choice for transferee forum. *See In re Comp. of Managerial, Prof'l & Technical Emp. Antitrust Litig.*, 206 F.Supp. 2d 1374, 1375 (J.P.M.L. 2002) (holding District of New Jersey is an “accessible, urban district[] equipped with the

resources that [a] complex docket is likely to require”); *In re: Nickelodeon Consumers Privacy Litig.*, 949 F. Supp. 2d 1377, 1378 (J.P.M.L. 2013) (same).

**C. In The Alternative, The Northern District Of Illinois Would Also Be An Appropriate Forum.**

As an alternative to transferring the Invokana cases to the District of New Jersey before Judge Martinotti, the Northern District of Illinois would be an appropriate forum with Judge Amy St. Eve presiding as transferee judge for several reasons.

First, Judge St. Eve is already assigned to one Invokana case—*Davis v. Janssen Pharmaceuticals, Inc.*, Case No. 3:16-08838. The Panel often considers districts—and judges—with pending cases for potential transfer. *See, e.g., In re 100% Grated Parmesan Cheese Mktg. & Sales Practices Litig.*, MDL Nos. 2705, 2707 & 2708, 2016 WL 3190426, at \*3 (J.P.M.L. June 2, 2016) (centralizing litigation before Judge Feinerman who was presiding over one potential tag-along action); *see also In re Premera Blue Cross Customer Data Sec. Breach Litig.*, 110 F. Supp. 3d 1358, 1360 (J.P.M.L. 2015) (centralizing in the District of Oregon where only one action was pending, and the other actions were all pending in a different district).

Second, while Judge St. Eve is presently overseeing two multidistrict litigations, both of these involve relatively few cases, leaving her with time to devote to this complex litigation. *See* [http://www.jpml.uscourts.gov/sites/jpml/files/Pending\\_MDL\\_Dockets\\_By\\_District-July-15-2016.pdf](http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-July-15-2016.pdf) (noting assignment to *In re: Rust-Oleum Restore Marketing, Sales Practices and Products Liability Litigation* and *In re: Herbal Supplements Marketing and Sales Practices Litigation*, with 7 and 71 actions pending respectively). It is not unusual for the Panel to assign a judge more than two active multidistrict litigations. *See, e.g., id.* (listing Judge Fallon overseeing three multidistrict litigations with more than 11,000 cases pending among the three and Judge Goodwin overseeing seven multidistrict litigations with more than 65,000 cases pending among

the seven). Moreover, Judge St. Eve is an experienced jurist who has served on the bench for over 14 years and has overseen five multidistrict litigations, giving her the necessary experience and proven track record to oversee this litigation.

Third, the Northern District has demonstrated the ability to efficiently and effectively manage its cases to handle another multidistrict litigation proceeding. The district ranks 20th out of 94 districts in time of filing to resolution of civil cases, with only 8% of its cases pending for over three years. See <http://www.uscourts.gov/statistics/table/na/federal-court-management-statistics/2016/06/30-1>. This is the type of efficient and effective case management that would be beneficial to a multidistrict litigation.

Fourth, the *Davis* action is pending in Chicago, Illinois, which has two airports with nonstop air service to and from many cities around the country. Chicago is also centrally located in the country, which mitigates travel burdens for parties and counsel coming from both coasts.

### **CONCLUSION**

For the foregoing reasons, Janssen respectfully requests that the Panel transfer the Invokana actions either to the District of New Jersey (preferably before Judge Martinotti) or the Northern District of Illinois (preferably before Judge St. Eve) for coordinated pretrial proceedings.

Dated: October 12, 2016

Respectfully submitted,

s/ John Q. Lewis

John Q. Lewis  
TUCKER ELLIS LLP  
950 Main Avenue, Suite 1100  
Cleveland, OH 44113-7213  
Telephone: 216.592.5000  
Facsimile: 216.592.5009  
john.lewis@tuckerellis.com

Counsel for Defendant Janssen Pharmaceuticals,  
Inc.

# EXHIBIT A

## Complex Litigation in New Jersey and Federal Courts: An Overview of the Current State of Affairs and a Glimpse of What Lies Ahead

*Hon. Brian R. Martinotti, J.S.C.\**

### INTRODUCTION

Complex, or aggregate, litigation arises in a variety of contexts, including class actions,<sup>1</sup> mass torts,<sup>2</sup> cases assigned for centralized

---

\* Judge Brian R. Martinotti was appointed to the Superior Court of New Jersey in February of 2002. Since March 2006, he has served in the Civil Division and was the Environmental and Mt. Laurel Judge until August 2011. In August 2009, the Chief Justice designated him as one of the State's three mass tort judges. Prior to this appointment, Judge Martinotti, a Certified Civil Trial Attorney, was a partner at Beattie Padovano, LLC, located in Montvale, New Jersey. He graduated from Fordham University in 1983 and Seton Hall Law School, *cum laude*, in 1986.

I would like to acknowledge and thank Philip W. Danziger, Esq., for his invaluable contributions to this Essay. Mr. Danziger served as my mass tort law clerk from 2011–2012 and was assigned primary responsibility for managing the multicounty litigations and centrally managed cases over which I preside. I owe him a great deal of gratitude for all his hard work, research, proofing, and rewriting for this Essay. He graciously (and promptly) responded to my 4:30 a.m. e-mails, and his ability to read my mind and know where I am going is only overshadowed by his ability to read my handwriting. Mr. Danziger consistently exceeded my expectations—and his job description—and I wish him nothing but the best as he embarks on what will be a very successful legal career. Finally, I would like to thank Jennifer Lahm, Mr. Danziger's successor as my multicounty litigation law clerk, for assisting with the final edits of this Essay and for continuing Mr. Danziger's high quality of work.

1. Class action lawsuits are governed by Rule 23 of the Federal Rules of Civil Procedure in federal courts, and New Jersey Court Rule 4:32 in New Jersey state courts. While class actions have a long history in the federal courts, their use was greatly enhanced by the 1966 amendment of Rule 23. Before this amendment, class actions had usually involved antitrust, securities, price-fixing, and Fair Labor Standards Act cases. The use of class actions for mass torts was neither intended nor expected by the framers of amended Rule 23, who assumed that common issues of fact and law would be outweighed by differences in the circumstances of the injuries, the injuries themselves, and in state laws. *See* FED. R. CIV. P. 23(f) advisory committee's notes. Nevertheless, class actions have become an effective way of challenging systematic discrimination or company-wide misconduct. Plaintiffs in class actions can craft remedies and injunctive relief far greater in scope than in an individual case. Class actions also put others on notice of potential deceptive practices of which they may not have been aware. Moreover, the class action enables individuals to pool their resources, share litigation risks and burdens, and more easily retain counsel for small value claims. Finally, the class action mechanism provides an efficient means of resolving similar claims in one lawsuit—relieving the courts of repetitive individual litigation and providing defendants with global peace. In sum, the class action lawsuit plays an important and unique role in the civil justice system. *See generally* DEBORAH R. HENSLER ET AL., CLASS ACTION DILEMMAS: PURSUING PUBLIC GOALS FOR PRIVATE GAIN

management,<sup>3</sup> and multidistrict litigation (“MDL”).<sup>4</sup> This Essay provides a brief overview of the various processes and management techniques of these complex cases<sup>5</sup> in the New Jersey and federal court systems.<sup>6</sup> This Essay also comments on the impact of the U.S. Supreme Court’s recent decisions in *Wal-Mart Stores, Inc. v. Dukes*<sup>7</sup> and *AT&T Mobility LLC v. Concepcion*<sup>8</sup> on the mass tort process. Lastly, this Essay addresses case management techniques in mass tort matters and the tools available to trial judges assigned to oversee such cases.<sup>9</sup>

---

(2000) (describing the pros and cons of class action lawsuits).

2. Mass torts may be distinguished from other personal injury claims in that mass torts involve large numbers of claims that are associated with a single product, property damage, or location. Despite the number of claimants, there must be a commonality of factual and legal issues, as well as a value interdependence between the different claims. See N.J. CT. R. 4:38-1(a). See also *infra* note 5 and accompanying text (noting that the term “mass tort” refers to complex litigation generally). Under Rule 4:38A (effective September 4, 2012), the Supreme Court removed the “mass tort” term altogether. Now, these cases will be referred to as “multicounty litigation,” or MCL. The term “mass tort,” however, continues to be used nationwide and can be used interchangeably with “multicounty litigation.”

3. Precipitating the recent amendment to Rule 4:38A was a shift in the nomenclature used to describe a centralized litigation, from “mass tort” to “centralized management.” This change in description can be seen as a minor benefit to defendants, as the term “mass tort” has proved somewhat inertial in driving up the number of cases filed following centralization under Rule 4:38A. There may also be public relations concerns for large, corporate defendants. The practical impact of the different terminology, however, remains the same. Once consolidated, designated litigations operate as a sort of “mini-MDL,” drawing plaintiffs from New Jersey and other states (or even other countries) who seek to take advantage of New Jersey rules and procedure.

4. Multidistrict litigation arises when civil litigation involving one or more common questions of fact is pending in different districts and such actions are transferred to any district for coordinated or consolidated pretrial proceedings. 28 U.S.C. § 1407(a) (2006). Such transfers are made by the Judicial Panel on Multidistrict Litigation (“JPML”). A judge (or judges) to whom such actions are assigned by the JPML conduct these coordinated or consolidated pretrial proceedings. The judge to whom such actions are assigned, the members of the JPML, and other circuit and district judges designated by the JPML may exercise the powers of a district judge in any district for the purpose of conducting pretrial depositions in such coordinated or consolidated pretrial proceedings. *Id.* § 1407(b).

5. Unless otherwise specified, hereinafter “mass tort” shall be used to refer to complex litigation, generally. This includes cases that have been assigned mass tort status or have been designated for centralized management, as well as those cases that have been consolidated before a single judge for pretrial and trial management to ensure consistent results but without the attendant formalities of being a “mass tort.”

6. Although this Essay is not intended to be a comprehensive analysis of the mass tort designation process, it should be mentioned that many states have established formal procedures for applying for mass tort status. See, e.g., CAL. CIV. PROC. CODE § 3.400 (West 2007); TEX. R. CIV. P. 42, PA. CT. C.P.R. 1701-1717; N.Y. C.P.L.R. 202.69 (CONSOL. 2012). For further commentary on various states’ procedures, see DAVID F. HERR, ANNOTATED MANUAL FOR COMPLEX LITIGATION FOURTH (2011 ed.).

7. 131 S. Ct. 2541 (2011).

8. 131 S. Ct. 1740 (2011).

9. More specifically, this Essay is a summary of the comments made at the recent Loyola

2012] *Complex Litigation in N.J. and Federal Courts* 563

At the beginning of September 2012, there were five active matters designated as a “mass tort” or assigned for centralized management in Bergen County, New Jersey: *In re NuvaRing Litigation*,<sup>10</sup> *In re YAZ/Yasmin/Ocella Litigation*,<sup>11</sup> *In re Prudential Life Insurance Co. of America Tort Litigation*,<sup>12</sup> *In re Alleged Environmental Contamination of Pompton Lakes*,<sup>13</sup> and *In re DePuy ASR Hip Implant Litigation*.<sup>14</sup> Combined with Atlantic and Middlesex Counties,<sup>15</sup> there are currently twenty such cases pending in New Jersey.<sup>16</sup> In contrast, there are more than 58,000 cases pending that have been consolidated as part of MDLs in the federal court system.<sup>17</sup>

There are, among others, two notable distinctions between the handling of complex litigation in the federal and New Jersey court systems. The first deals with the designation process itself, i.e., how the parties (or court) apply for mass tort status, the factors a court must

---

University Chicago Law Journal Symposium, *The Future of Class Actions and Its Alternatives*.

10. Docket No. BER-L-3081-09 (N.J. Sup. Ct. Law Div.) (alleging that the plaintiffs suffered damages from use of the NuvaRing® contraceptive ring, including death, tissue and organ breakdown that occasionally necessitated amputation, heart attacks, and ischemic strokes). At of the beginning of September 2012, there had been four cases filed in New Jersey alleging that women died due to deep vein thrombosis (DVT) resulting from their use of NuvaRing®: *Estate of Bozicev v. Organon USA*, BER-L-2869-09; *Estate of Ramsey v. Organon USA*, BER-L-2879-09; *Cox v. Organon USA*, BER-L-2877-09; and *Huff v. Organon USA*, BER-L-7670-09.

11. Docket No. BER-L-3572-10 (N.J. Sup. Ct. Law Div.) (alleging damages arising from the use of the oral contraceptives Yaz, Yasmin, and the generic drug Ocella).

12. Docket No. BER-L-2251-10 (N.J. Sup. Ct. Law Div.) (alleging commercial bribery and other torts against Prudential Life Insurance Company of America brought by former employees).

13. Docket No. BER-L-10803-10 (N.J. Sup. Ct. Law Div.) (seeking damages for environmental contamination allegedly caused by the defendant corporations brought by current and former residents of Pompton Lakes, Passaic County, New Jersey).

14. Docket No. BER-L-3971-11 (N.J. Sup. Ct. Law Div.) (alleging damages and injuries caused by ASRT hip implants where, after five years, thirteen percent of patients who received the ASRT hip implants needed to have a second hip replacement surgery (revision surgery)).

15. Hon. Carol E. Higbee, P.J.Cv., sits in Atlantic County, and Hon. Jessica R. Mayer, J.S.C., sits in Middlesex County.

16. Currently, there are twelve cases designated as a “mass tort,” and eight cases designated for “centralized management.” Many, but not all, of these cases involve pharmaceuticals or medical devices. For further information on all prior and pending mass torts in New Jersey, see *Multicounty Litigation Center*, NEW JERSEY COURTS, <http://www.judiciary.state.nj.us/mass-tort/index.htm> (last visited Oct. 20, 2012). Prior cases in Bergen County include: *In re Diet Drug & Fen Phen Litigations*, Docket Nos. BER-L-13379-04 and BER-L-7589-05 (N.J. Sup. Ct. Law Div.); *In re Long Branch Manufactured Gas Plant Litigation*, Docket No. BER-L-8839-04 (N.J. Sup. Ct. Law Div.); *In re Depo-Provera Litigation*, Docket No. BER-L-4889-07 (N.J. Sup. Ct. Law Div.); *In re Alleged Mahwah Toxic Dump Site*, Docket No. BER-L-489-08 (N.J. Sup. Ct. Law Div.); *In re Zelnorm Litigation*, Docket No. BER-L-7590-08 (N.J. Sup. Ct. Law Div.); and *In re Digitek Litigation*, Docket No. BER-L-917-09 (N.J. Sup. Ct. Law Div.).

17. There are frequently matters pending in the MDL and several state courts. This raises a myriad of issues, most notably the level of cooperation by and among federal and state courts. See *infra* Part I (discussing the standard for mandamus review).



consider when evaluating such an application, and the manner in which a court's determination may be appealed. The second addresses the manner in which these cases are managed and tried in each respective court system.

#### I. MASS TORT DESIGNATION AND APPEALS PROCESSES IN FEDERAL AND STATE COURTS

Rule 23 of the Federal Rules of Civil Procedure and 28 U.S.C. § 1407 govern the class action and mass tort application processes in the federal courts, respectively. Rule 23(b) provides for three types of class actions, each with its own specific requirements.<sup>18</sup> All class action suits, however, must satisfy the following prerequisites: (1) “the class is so numerous that joinder of all members is impracticable” (numerosity); (2) “questions of law or fact common to the class” (commonality); (3) “the claims or defenses of the representative parties are typical of the claims or defenses of the class” (typicality); and (4) “the representative parties will fairly and adequately protect the interests of the class” (representativeness).<sup>19</sup>

However, in the wake of *Dukes*, judges, practitioners, and academics alike can agree that class certification has become increasingly difficult for plaintiffs to obtain.<sup>20</sup> Plaintiffs must show “significant proof” to

---

18. See FED. R. CIV. P. 23(b)(1)–(3) (listing the three circumstances under which a class action may be maintained).

19. FED. R. CIV. P. 23(a)(1)–(4).

20. In *Dukes*, the Court held that, under Rule 23, a class action case alleging intentional employment discrimination could not proceed when individual supervisors at different stores made the allegedly discriminatory decisions. *Wal-Mart Stores, Inc. v. Dukes*, 131 S. Ct. 2541, 2556–57 (2011). The majority opinion in *Dukes* increased the difficulty of proving a common question of law or fact under Rule 23(a) by requiring “significant proof” to which the trial court must extend a “rigorous analysis.” *Id.* at 2551–53. Although the Court did not provide much detail as to what a “significant proof” standard should entail, by rejecting plaintiffs’ proof, the Court seemed to indicate that the standard essentially requires a determination of the merits at the time of class certification, and demands a higher level of specificity and expert and scientific evidence than previously required. *Id.* See also *Gen. Tel. Co. of Sw. v. Falcon*, 457 U.S. 147, 160–61 (1982) (finding that “sometimes it may be necessary for the court to probe behind the pleadings before coming to rest on the certification question,” and that certification is proper only if “the trial court is satisfied, after a rigorous analysis, that the prerequisites of Rule 23(a) have been satisfied”). In so doing, the Court suggested that the *Daubert* standard for introduction of scientific proof at trial would also apply at the class certification stage. *Dukes*, 131 S. Ct. at 2551–53. See also *Daubert v. Merrell Dow Pharms., Inc.*, 509 U.S. 579, 584–89 (requiring the trial judge, faced with a proffer of expert scientific testimony, to make a “preliminary assessment of whether the testimony’s underlying reasoning or methodology is scientifically valid and properly can be applied to the facts at issue,” and providing a non-exhaustive list of factors to be considered, including whether the theory or technique in question can be tested, whether it has been subjected to peer review and publication, and whether it has attracted widespread acceptance within a relevant scientific community). The standard essentially requires the proponent to demonstrate that an expert’s conclusions are the product of sound scientific methodology, and not

2012] *Complex Litigation in N.J. and Federal Courts* 565

satisfy the commonality requirement for class certification.<sup>21</sup> Now, the burden is placed on an individual district judge to conduct a rigorous analysis, at times overlapping with the merits of the plaintiffs' underlying claims, to determine whether to grant class certification.<sup>22</sup> This has become a difficult hurdle for plaintiffs—judges are applying *Dukes*'s “significant proof” and “rigorous analysis” standards to deny class certification at the district court level.<sup>23</sup>

*Dukes* results in an interesting dichotomy. Aggrieved litigants may attempt to utilize the MDL process more readily to circumvent the rigorous analysis a district court judge must undertake following the *Dukes* decision. Unlike the “significant proof” standard required for class certification, the MDL process, which is governed by 28 U.S.C. § 1407, is overseen by the Judicial Panel on Multidistrict Litigation (“JPML”).<sup>24</sup> The JPML is not required to undertake a rigorous analysis. Instead, the panel relies on its experience—to which a reviewing court affords extreme deference—to determine the appropriateness of consolidating or transferring a case to a federal MDL.<sup>25</sup> Unlike the requirements for class certification, 28 U.S.C. § 1407 provides: “When civil actions involving one or more common questions of fact are pending in different districts, such actions may be transferred to any district for coordinated or consolidated pretrial proceedings.”<sup>26</sup> The

---

merely based on a scientific technique that has been “generally accepted,” as was previously required. *Id.* Accord FED. R. EVID. 702 (adopting the *Daubert* standard for expert testimony admissibility).

21. *Dukes*, 131 S. Ct. at 2551–53. Similarly, in *AT&T Mobility LLC v. Concepcion*, the Court held that, because there is no inherent right to try a case as a class action, arbitration clauses that waived the right to prosecute a class action were not per se unconscionable, thus making it easier for defendants to opt out of class-wide arbitration clauses in contracts. 131 S. Ct. 1740, 1750–52 (2011). See also *NAACP v. Foulke Mgmt. Corp.*, 24 A.3d 777, 791 (N.J. Super. Ct. App. Div. 2011) (discussing the rationale of the Court in *Concepcion* which allowed defendants to more easily opt out of contractual class-wide arbitration clauses).

22. *Dukes*, 131 S. Ct. at 2551 (Rule 23 “certification is proper only if ‘the trial court is satisfied, after a rigorous analysis, that the prerequisites of Rule 23(a) have been satisfied’ . . . .”) (citations omitted) (quoting *Falcon*, 457 U.S. at 160).

23. See, e.g., *Cruz v. Dollar Tree Stores, Inc.*, 2011 U.S. Dist. LEXIS 73938, at \*16–17 (N.D. Cal. July 7, 2011) (decertifying a class in light of *Dukes*'s “forceful affirmation of a class action plaintiff's obligation to produce common proof of class-wide liability in order to justify class certification”). See also Daniel Leonard, Jocelyn Larkin, Paul Smith & Hon. Emmet Sullivan, ABA Section of Litigation 2012, *Putting Wal-Mart Stores v. Dukes to the Test: Can This Class Be Certified?* (2012) (listing Post-*Dukes* Rule 23 certification cases and their outcomes as of February 2012).

24. The JPML consists of seven circuit and district judges designated from time to time by the Chief Justice of the United States, no two of whom shall be from the same circuit. 28 U.S.C. § 1407(d) (2006). The concurrence of four members is necessary for any action by the panel. *Id.*

25. See, e.g., *FedEx Ground Package Sys., Inc., v. U.S. JPML*, 662 F.3d 887, 890 (7th Cir. 2011).

26. 28 U.S.C. § 1407. Each action so transferred is remanded by the panel at or before the

JPML's determination as to whether to transfer actions is based on the convenience of parties and witnesses, and is made in an effort to promote just and efficient conduct of such actions. It seems clear that rigorous analysis standard for class certification under Rule 23 is much higher than the largely discretionary standard employed by the JPML.

The processes for appealing a court's class certification order or transfer for consolidation or coordinated proceedings varies greatly by jurisdiction and type of relief sought. Rule 23(f), which governs an appeal of a district court's decision of whether to grant class certification,<sup>27</sup> was adopted to expand the discretion of Courts of Appeals to grant interlocutory review of class certification rulings. The Rule was intended to be broad in scope and vested "[t]he courts of appeals [with] develop[ing] standards for granting review that reflects the changing areas of uncertainty in class litigation."<sup>28</sup>

Relying on the Advisory Committee's Notes, the Seventh Circuit first held that interlocutory review is appropriate when the denial of class certification sounds the "death knell" for plaintiffs whose "claim is too small to justify the expense of litigation," or defendants facing claims where "the stakes are large and the risk of a settlement or other disposition that does not reflect the merits of the claim is substantial."<sup>29</sup> The Seventh Circuit further held that interlocutory review is proper when an appeal involves a "fundamental issue" relating to class actions.<sup>30</sup> Both the First and the Second Circuits have largely adopted the Seventh Circuit's approach.<sup>31</sup> The Third, Ninth, Tenth, and D.C. Circuits have expanded upon the approach, adopting "manifest error" in the class certification ruling as an independent and adequate ground for interlocutory review thereof.<sup>32</sup> The Fourth, Sixth, and Eleventh Circuits

---

conclusion of such pretrial proceedings to the district from which it was transferred unless it shall have been previously terminated.

27. FED. R. CIV. P. 23(f) ("A court of appeals may permit an appeal from an order granting or denying class-action certification under this rule if a petition for permission to appeal is filed . . . within 14 days . . . . An appeal does not stay proceedings in the district court unless . . . so order[ed].").

28. FED. R. CIV. P. 23(f) advisory committee's note (1998) (noting the Courts of Appeals have "unfettered discretion . . . akin to the discretion exercised by the Supreme Court in acting on a petition for certiorari").

29. *Blair v. Equifax Check Servs., Inc.*, 181 F.3d 832, 834–35 (7th Cir. 1999).

30. *Id.* at 835.

31. *Sumitomo Copper Litig. v. Credit Lyonnais Rouse, Ltd.*, 262 F.3d 134, 139 (2d Cir. 2001) (adopting the Seventh Circuit approach without modification); *Waste Mgmt. Holdings, Inc. v. Mowbray*, 208 F.3d 288, 294 (1st Cir. 2000) (concluding that Rule 23(f) review is appropriate in cases involving a fundamental issue only if it is "important to the particular litigation as well as important in itself and likely to escape effective review if left hanging until the end of the case").

32. *See Newton v. Merrill Lynch, Pierce, Fenner & Smith, Inc.*, 259 F.3d 154, 165 (3d Cir. 2001); *Chamberlain v. Ford Motor Co.*, 402 F.3d 952, 959 (9th Cir. 2005); *Vallario v. Vandehey*,

2012] *Complex Litigation in N.J. and Federal Courts* 567

have adopted a “five factor sliding scale” test in deciding whether to grant review.<sup>33</sup> Under this test, the courts of appeal uses a “sliding scale” to determine whether the district court erred in deciding to grant or deny review.<sup>34</sup> Rule 23(f) is still evolving, varies by circuit, and has resulted in a relatively small number of interlocutory appeals.<sup>35</sup>

With respect to the appeal of the JPML’s determinations, on the other hand, 28 U.S.C. § 1407 makes clear that “[t]here shall be no appeal or review of an order of the panel denying a motion to transfer for consolidated or coordinated proceedings.”<sup>36</sup> The statute further requires that appeals of JPML orders be brought in the circuit court with jurisdiction over the case or transferee court.<sup>37</sup> This is a high standard for relief. To qualify for mandamus relief, a party must show that it has no other means to obtain relief.<sup>38</sup> Litigants often satisfy this first requirement because “[n]o proceedings for review of any order of the [JPML] may be permitted except by extraordinary writ.”<sup>39</sup> Next, a litigant must show that his or her right to the writ is clear and indisputable and a reviewing court must be satisfied that the writ is appropriate under the circumstances.<sup>40</sup> Moreover, “only exceptional circumstances amounting to a judicial usurpation of power or a clear abuse of discretion will justify the invocation of this extraordinary remedy.”<sup>41</sup> The Seventh Circuit has been observed that

a transferee district court knows well the issues and dynamics of [a] particular case. The JPML brings to bear decades of experience with more than a thousand MDL proceedings, which have included some of

---

554 F.3d 1259, 1263–64 (10th Cir. 2009); *In re Lorazepam & Clorazepate Antitrust Litig.*, 289 F.3d 98, 105 (D.C. Cir. 2002).

33. See *Lienhart v. Dryvit Sys., Inc.*, 255 F.3d 138, 144–46 (4th Cir. 2001); *In re Delta Air Lines*, 310 F.3d 953, 960 (6th Cir. 2002); *Prado-Steiman v. Bush*, 221 F.3d 1266, 1274–76 (11th Cir. 2000).

34. See *Prado-Steiman*, 221 F.3d at 1275 n.10 (“The stronger the showing of an abuse of discretion, the more this factor weighs in favor of interlocutory review.”); *Lienhart*, 255 F.3d at 145–46; *In re Delta Air Lines*, 310 F.3d at 960. These courts also consider the status of the litigation in the district court, particularly the progress of discovery.

35. See Barry Sullivan & Amy Kobelski Trueblood, *Rule 23(f): A Note on Law and Discretion in the Courts of Appeals*, 246 F.R.D. 277, 290 (2008) (providing circuit-by-circuit data on the number of petitions filed and the percentage of those petitions granted).

36. 28 U.S.C. § 1407 (2006).

37. See, e.g., Order, *In re Shannon McConnell* (6th Cir. Apr. 6, 2012) (No. 11-4265) (denying appeal of the JPML’s transfer of products liability case from the United States District Court for the Southern District of Florida to the United States District Court for the Northern District of Ohio for consolidated pretrial proceedings in *In re DePuy Orthopaedics, Inc., ASR Hip Implant Prods. Liab. Litig.*, 753 F. Supp. 2d 1378 (J.P.M.L. 2010)).

38. *Cheney v. U.S. Dist. Court for D.C.*, 542 U.S. 367, 380 (2004).

39. 28 U.S.C. § 1407.

40. *Cheney*, 542 U.S. at 381.

41. *Id.* at 380 (internal quotation marks and ellipses omitted).

the most complex and challenging cases in the history of the federal courts. The choice between . . . methods of case management is an archetype for a discretionary judgment, and the transferee court and the JPML are in the best position to make that judgment. In terms of the standards for issuing writs of mandamus, it would be rare for one party to have a “clear and indisputable right” to one method over the other.<sup>42</sup>

In general, a reviewing court will defer to the JPML’s exercise of its discretion, which gives rise to the imprimatur of reasonableness as the panel’s decisions are essentially presumed valid and reasonable.<sup>43</sup> This deference presents a difficult hurdle for appellants seeking to challenge transfer or consolidation.<sup>44</sup> It seems likely, then, that there will be a trend toward mass torts and MDLs (or centrally managed litigations) as opposed to class actions, which have become increasingly difficult to obtain.<sup>45</sup>

In New Jersey, on the other hand, the multicounty litigation (MCL)

42. *FedEx Ground Package Sys., Inc. v. U.S. JPML*, 662 F.3d 887, 891 (7th Cir. 2011).

43. *See, e.g., id.* (“The choice between . . . methods of case management is an archetype for a discretionary judgment, and the transferee court and the JPML are in the best position to make that judgment.”). Because “the fact-specific nature of MDL litigation call[s] for leaving such case-management decisions to the sound discretion of the transferee court and the JPML,” *id.*, litigants challenging the JPML’s exercise of discretion rarely meet the standard for mandamus relief.

44. *See Order, In re Shannon McConnell* (6th Cir. Apr. 6, 2012) (No. 11-4265) (denying party’s appeal of JPML’s transfer of products liability actions).

45. Whether there is class certification, mass tort litigation is complex litigation in which the judge must define problems and actively shape the litigation. Indeed, in 2002, the Judicial Conference changed class action rules to give the judge greater ability to shape class actions, including more influence over the selection of lawyers to represent the class and greater control over lawyers’ fees. *See* Letter from David F. Levi, Advisory Comm. on the Fed. Rules of Civil Procedure, to Honorable Anthony J. Scirica, Standing Comm. on Rules of Practice and Procedure (May 20, 2002) (describing amendments); Linda Greenhouse, *Judges Back Rule Changes for Handling Class Actions*, N.Y. TIMES, Sept. 25, 2002, at A18. There may be hundreds of thousands of plaintiffs, multiple defendants, and numerous lawyers to be responsible during discovery (or at least to back up the magistrate judge). Third, fourth, and fifth parties such as insurance companies and governments may be involved.

The judge and/or magistrate judge must decide hundreds of procedural and evidentiary motions. The judge must decide whether to certify a class, determine subclasses, and decide how to deal with future mass tort claimants. He must grapple with complex issues of jurisdiction, choice of law, preemption, statutes of limitations, and burdens of proof. He must attempt to understand and try to help the jurors understand scientific evidence and separate “good science” from “junk science,” coordinate with state (or federal) judges, appoint settlement (and special) masters, decide whether a settlement is fair, determine proper attorneys’ fees, and hold “fairness hearings.” JEFFREY B. MORRIS, LEADERSHIP ON THE FEDERAL BENCH: THE CRAFT AND ACTIVISM OF JACK WEINSTEIN 319 (2011). *See also* Joseph M. Price & Ellen S. Rosenberg, *The Silicone Gel Breast Implant Controversy: The Rise of Expert Panels and the Fall of Junk Science*, 93 J. ROYAL SOC’Y MED. 31, 33 (2000) (advocating for “a vigorous enforcement of the *Daubert* standards and the requirements of sound science by the courts” through the use of expert science panels).

2012] *Complex Litigation in N.J. and Federal Courts* 569

application and designation process is governed by Rule 4:38A<sup>46</sup> of the Rules Governing Civil Practice in the Superior Court, Tax Court, and Surrogate's Courts.<sup>47</sup> The Rule provides:

The Supreme Court may designate a case or category of cases as a mass tort to receive centralized management in accordance with criteria and procedures promulgated by the administrative Director of the Courts upon approval by the Court. Promulgation of the criteria and procedures will include posting in the Mass Tort Information Center on the Judiciary's Internet website ([www.judiciary.state.nj.us](http://www.judiciary.state.nj.us)).<sup>48</sup>

The guidelines issued in conjunction with Rule 4:38A set forth a procedure for requesting mass tort designation.<sup>49</sup> The process permits an attorney involved in the case (most often plaintiffs' attorneys) or the assignment judge of any vicinage to apply to the New Jersey Supreme Court to have a group of factually and legally similar cases classified as a mass tort and assigned a designated judge for centralized management. Upon receipt of such an application, the Administrative Office of the Courts ("AOC") publishes a notice about the case to all parties involved, to the bar in legal newspapers, and on the Judiciary's website. Following publication, the AOC accepts comments and objections to the application for a defined time period before deciding whether to grant or deny the application.

In reviewing an application for mass tort designation or centralized

---

46. All subsequent textual references to New Jersey "Rules" are to the Rules Governing Civil Practice in the Superior Court, Tax Court, and Surrogate's Courts.

47. Prior to 2003, there had been much comment and discussion surrounding how courts in New Jersey should handle mass tort claims. See Michael Dore, *Reforming the New Jersey Supreme Court's Procedures for Consolidating Mass Tort Litigation: A Proposal for Disclosing the Rules of the Game*, 55 RUTGERS L. REV. 591 (2002) (criticizing the New Jersey Supreme Court for lack of transparency and predictability in consolidation proceedings). Mass tort coordination efforts began with the Supreme Court's consolidation of all Johns-Manville asbestos matters for case management by Hon. John E. Keefe in Middlesex County. *Mass Tort Advisory Committee Report to the New Jersey Supreme Court*, 154 N.J. L.J. 528, 528 (Nov. 9, 1998). Following the asbestos consolidation order, the Supreme Court centralized other significant litigations in Middlesex County, but failed to disclose the procedures that had been used to decide the coordinated treatment of these cases. The successful handling of these matters led to a proposal of a blue ribbon committee for the formation of a single mass tort court in Middlesex County. *Id.* Although the Mass Tort Advisory Report was widely praised, the Supreme Court rejected its proposals. *Supreme Court of New Jersey Administrative Determinations Report of the Mass Tort Advisory Committee*, 157 N.J. L.J. 696, 696 (Aug. 16, 1999). This prompted the Court, in October 2003, to formally promulgate Rule 4:38A to provide for the centralized management of mass torts in New Jersey. Michael Dore, *The New Jersey Mass Tort Designation Process: Who Decides What Kind of Cases Go Where?*, N.J. LAW., Aug. 2011, at 12.

48. N.J. CT. R. 4:38A.

49. See N.J. COURTS, MULTICOUNTY LITIGATION GUIDELINES, DIRECTIVE #08-12, available at <http://www.judiciary.state.nj.us/notices/2012/n120809b.pdf> (discussing the procedure for requesting mass tort designation pursuant to Rule 4:38A).

management, the court must consider whether: (1) the case involves a large numbers of parties; (2) the case involves numerous claims with common, recurrent issues of law and fact that are related to a consumer product, mass disaster, or environmental or toxic tort; (3) the parties to the litigation are geographically disbursed; (4) there is a high degree of commonality among the plaintiffs' injuries or damages; and (5) there is a "value interdependence" between different claims (i.e., the strength or weakness of the causation and liability aspects of the case are often "dependent upon the success or failure of similar lawsuits in other jurisdictions").<sup>50</sup>

## II. MASS TORT CASE MANAGEMENT PROCESS IN FEDERAL AND STATE COURTS

### A. *Case Management Conference and Order*

Once the AOC determines a case is appropriate for mass tort status or centralized management, the New Jersey Supreme Court issues an order memorializing the same. The mass tort judge assigned to preside over the case will then set up the initial Case Management Conference ("CMC") and issue an initial Case Management Order ("CMO").

An important distinction between federal MDLs and New Jersey MCLs is the court in which those cases are actually tried. In the federal system, the MDL court must remand the case to its original jurisdiction following the completion of pretrial proceedings.<sup>51</sup> In New Jersey,

---

50. *See id.* There are, of course, other factors to be considered, including, but not limited to: [The] degree of remoteness between the court and actual decision-makers in the litigation[;] . . . whether there is a risk that centralization may unreasonably delay the progress, increase the expense, or complicate the processing of any action, or otherwise prejudice a party, whether centralized management is fair and convenient to the parties, witnesses and counsel; whether there is a risk of duplicative and inconsistent rulings, orders or judgments if the cases are not managed in a coordinated fashion; whether coordinated discovery would be advantageous; whether the cases require specialized expertise and case processing as provided by the dedicated multicounty litigation judge and staff; whether centralization would result in the efficient utilization of judicial resources[;] . . . [and] whether there are related matters pending in Federal court or in other state courts that require coordination with a single New Jersey judge.

*Id.*

Independent of these guidelines, in July 2005, the New Jersey Judiciary published a Mass Tort Resource Book ("Resource Book") to address issues that arise in mass tort litigation from the case's designation through resolution. NEW JERSEY JUDICIARY, NEW JERSEY MASS TORT (NON-ASBESTOS) RESOURCE BOOK (3d ed. 2007), *available at* [http://www.judiciary.state.nj.us/mass-tort/MassTortSOP\\_NonAsbestosNovember2007WebVersion.pdf](http://www.judiciary.state.nj.us/mass-tort/MassTortSOP_NonAsbestosNovember2007WebVersion.pdf). The Resource Book explains to practitioners how mass tort coordination decisions are made, how these cases are administered, and the process the Court will use to send these cases to one of the three mass tort venues in the State. *See id.* at 2–5.

51. FED. R. P. J.P.M.L. 7.6.

2012] *Complex Litigation in N.J. and Federal Courts* 571

MCL cases are tried in the county in which those cases have been transferred or consolidated.<sup>52</sup> As a result, for the state trial judge, venue rules are superseded by the court's consolidation order. Therefore, a litigant will have her pretrial managed and tried by the same judge and trial before a jury from a county that would not otherwise have proper venue pursuant to Rule 4:3-2 or 4:3-3.<sup>53</sup>

Once a case has been designated a mass tort or assigned for centralized management, a trial or managing judge will issue a comprehensive CMO.<sup>54</sup> This initial order sets forth the "ground rules" for the litigation, including the court's expectations and requirements of the parties and their legal counsel.<sup>55</sup> Furthermore, the initial CMO provides a framework for the litigation. Future CMOs may be divided into subparts; e.g., "compliance with prior orders," "case management," and "substantive motions." As the litigation progresses, subsequent CMOs detail the flow of the litigation. The initial order will also schedule the first CMC. At that conference, liaison counsel may be selected. Liaison counsel is similar to a steering committee and serves as a filter/representative for all counsel when addressing the court.

As these complex cases often remain pending in other courts for some time prior to the transfer or consolidation order, it is beneficial for the trial or managing judge to keep in frequent contact with counsel,

---

52. To illustrate by example: Suppose a New Jersey plaintiff files a case in Morris County, New Jersey, and that case is later assigned to Atlantic County for centralized management. The case will be tried in Atlantic County. However, if the same plaintiff files her claim in the Federal District Court for New Jersey, and that case is consolidated under a federal MDL in the Sixth Circuit, the case would be managed by the MDL judge for pretrial proceedings, but would be remanded to the District of New Jersey for trial. There are, however, techniques to overcome this requirement.

53. N.J. CT. R. 4:3-2(a) (providing that venue "shall be laid in the county in which the cause of action arose, or in which any party to the action resides at the time of its commencement, or in which the summons was served on a nonresident defendant . . ."). See also N.J. CT. R. 4:3-3(a) (noting that "a change of venue may be ordered by the Assignment Judge or the designee of the Assignment Judge of the county in which venue is laid . . . (1) if the venue is not laid in accordance with R. 4:3-2; or (2) if there is a substantial doubt that a fair and impartial trial can be had in the county where venue is laid; or (3) for the convenience of the parties and witnesses in the interest of justice"). Thus, when a group of similar cases become consolidated as part of a multicounty litigation, it may lead to a trial in a county that does not provide the ideal jury pool for individual plaintiffs or defendants.

54. See, e.g., Initial Order for Case Management, *In re Yaz, Yasmin, Ocella Litigation* (N.J. Super. Ct. Law Div. 2010) (No. 287), available at [http://www.judiciary.state.nj.us/mass-tort/yaz/yaz\\_init\\_cmo.pdf](http://www.judiciary.state.nj.us/mass-tort/yaz/yaz_init_cmo.pdf). Given the unique factual and legal issues presented, judges can be creative when crafting orders and have much discretion and flexibility in their management of these cases. Frequently, they are in uncharted waters and there is little or no precedent when confronted with issues.

55. In the initial CMO, or any subsequent CMO, a court may require the use of a particular plaintiff/defendant fact sheet or short form complaint/answer to enable a judge to quickly review a particular plaintiff's or defendant's underlying cause of action and/or defenses.



either through regularly held (often monthly) in-person CMCs, telephonic status conferences, or e-mail status updates. This practice allows a mass tort trial judge to keep his or her finger on the pulse of the litigation, which, in turn, will help to avoid voluminous motion practice and permit an expeditious flow of the litigation.<sup>56</sup>

### B. Case Management Techniques

There are a number of case management techniques that a mass tort judge might employ at various stages of the litigation with the goal of streamlining the process for the parties and the court. Among these tools are *Lone Pine* orders, *Stempler* interviews, appointment of special masters, use of bellwether trials, and state and federal judge cooperation.

*Lone Pine* orders refer generically to a case management order that requires plaintiffs in potentially large or complex cases to define their alleged injuries and/or damages and demonstrate at the outset some minimal level of evidentiary support for key components of their claims, usually causation of damages.<sup>57</sup> The traditional rationale for such orders is that they seek to ensure that completely unsupported claims will not consume the judge's or litigants' resources.<sup>58</sup> Thus, *Lone Pine* orders typically require plaintiffs to provide case-specific expert reports establishing a basis for their claims—i.e., that their injuries were caused by the defendant's conduct—and the scientific basis for the experts' opinions.<sup>59</sup> Although *Lone Pine* orders are relatively rare in New Jersey mass tort jurisprudence, they have been

---

56. Of course, there are a myriad of complex substantive and procedural motions that are filed in mass tort litigations, including jurisdictional and preemption arguments, *Daubert/Kemp* motions (as to expert testimony and underlying science), and privilege. Because of the unique factual and legal issues involved in mass torts and MDLs, judges are afforded great latitude and deference in the handling of such matters. This includes the use of creative case management and scheduling orders that otherwise may not be sanctioned. For example, a judge may require counsel to seek and receive permission of the Court prior to filing any substantive motions.

57. *Lore v. Lone Pine Corp.*, No. L 33606-85, 1986 N.J. Super. LEXIS 1626 (N.J. Super. Ct. Law Div. Nov. 18, 1986).

58. *Baker v. Chevron USA, Inc.*, No. 1:05-CV-227, 2007 U.S. Dist. LEXIS 6601, at \*2 (S.D. Ohio Jan. 30, 2007) (“The basic purpose of a *Lone Pine* order is to identify and cull potentially meritless claims and streamline litigation in complex cases involving numerous claimants.”).

59. The critical point to remember with *Lone Pine* orders is that whatever perceived burdens they place on the plaintiffs must be weighed against the burdens protracted litigation will impose on the court system and the defendant. They do not, as plaintiffs often argue, unfairly require the plaintiffs to prove their case before proceeding with the lawsuit. They merely require plaintiffs to define their claims clearly and to demonstrate that there is some competent evidentiary support to justify proceeding with time consuming, burdensome, and complex litigation. MANUAL FOR COMPLEX LITIGATION (FOURTH) §§ 10.1–11.33 (2004).

2012] *Complex Litigation in N.J. and Federal Courts* 573

successfully employed in complex cases in many other states.<sup>60</sup>

*Stempler* interviews are informal *ex parte* conferences with a non-party treating physician, on notice to the plaintiff-patient.<sup>61</sup> It is essentially “cheap” discovery (as opposed to a deposition on the record). When a plaintiff unreasonably withholds an authorization for the interview of a non-party treating physician, production of such authorization “can be compelled . . . by motion.”<sup>62</sup> In *Stempler v. Speidel*, the New Jersey Supreme Court set forth the following conditions for defense counsel’s *ex parte* contact with a physician when the Court orders such contact in response to a motion to compel: (1) provide the treating physician with a description of the anticipated scope of the interview; (2) communicate with “unmistakable clarity” that the physician’s participation in the *ex parte* interview is voluntary; and (3) provide plaintiff’s counsel with reasonable notice of the time and place of the proposed interview.<sup>63</sup>

As issues arise, usually at the monthly CMCs, the court will order counsel to “meet and confer” about the issues. Of course, it is expected that counsel would discuss issues with each other prior to seeking court intervention. Remarkably, however, it is often not until they are ordered to engage each other that the parties resolve (or substantially resolve) these issues amongst themselves. Perhaps a reason for that success is, as disputed issues are discussed at CMCs, counsel can get a feeling as to how a judge may rule on the disputed issue(s) that may temper their positions with opposing counsel. Thus, the meet and confer session may be more successful than it would have been without the court’s “musings.”

The special master’s role in complex litigation is to supervise those falling under the order of the court to ensure that court orders are followed, and to report to the judge on the activities of the entity being supervised. Often, but not exclusively, these roles arise in MDL cases, class actions, or other complex or multiparty litigation. Special masters

---

60. See, e.g., M. Bernadette Welch, *Propriety and Application of Lone Pine Orders Used to Expedite Claims and Increase Judicial Efficiency in Mass Tort Litigation*, 57 A.L.R. 6th 383, 392 (2010) (“In recent years, both federal and state courts have begun using *Lone Pine* orders during the pre-discovery phase in cases involving mass tort claims as a means of streamlining case management and promoting efficient case resolution. *Lone Pine* orders generally require plaintiffs to identify their injuries with specificity and produce some evidence of causation, enabling courts to focus their attention on scientific and technical issues at the beginning of a case instead of having to wait for the actual trial.”).

61. *Stempler v. Speidel*, 495 A.2d 857 (N.J. 1985). See also *In re Pelvic Mesh/Gynecare Litig.*, 43 A.3d 1211, 1220–21 (N.J. Super. App. Div. 2012) (discussing the considerations and holding of the *Stempler* court).

62. *Stempler*, 495 A.2d at 864.

63. *Id.*

take on several types of roles, including: settlement master; discovery master; coordinating master; trial master; expert advisor; technology master; claims administrator; receiver; criminal case master; conference judge; and appellate master.<sup>64</sup> Each of these special masters serves a discrete function and aids the court, in particular, with discovery disputes and settlements. Rule 53 of the Federal Rules of Civil procedure governs the appointment of masters in federal courts.<sup>65</sup> In New Jersey, the state court rules require the approval by the Chief Justice of the Supreme Court to appoint masters in mass torts.<sup>66</sup>

As discovery draws to a close, bellwether trials become another important case management tool often used in mass tort and MDL cases.<sup>67</sup> The court schedules the selection of bellwether trials, which are essentially trials to indicate future trends in a specific litigation. The trial selection process varies.<sup>68</sup> Some courts choose a random sample of cases to try to a jury, others require counsel to submit a list of cases to choose from, while others leave the selection of trial cases to counsel. The judge may then bifurcate the cases into liability and damages phases, or perhaps even trifurcate them into liability, causation, and damages phases. The parties try each bellwether case before a jury that renders a verdict in that particular case. Finally, the results of the bellwether trials are extrapolated to the remaining plaintiffs. The underlying principle of such an extrapolation is that the bellwether plaintiffs are *typical* of the rest of the plaintiff group such that the results of the bellwether trials represent the *likely outcome* of their cases.<sup>69</sup> This information is intended to help facilitate settlement by providing counsel insight as to the true value of the claims involved. There are times, however, that a bellwether trial will not help advance

---

64. See ACADEMY OF COURT-APPOINTED MASTERS, APPOINTING SPECIAL MASTERS AND OTHER JUDICIAL ADJUNCTS (2d ed. 2009) (describing the various types of special masters and their use in complex litigations).

65. FED. R. CIV. P. 53 (outlining the appointment process, scope of authority, and compensation of special masters in federal courts).

66. N.J. CT. R. 4:41. For a discussion of the role of special masters in a non-mass tort setting, see *Zehl v. Elizabeth Bd. of Educ.*, 43 A.3d 1188, 1193–96 (N.J. Super. Ct. App. Div. 2012).

67. See *Perez v. Wyeth Labs. Inc.*, 734 A.2d 1245, 1248 n.2 (N.J. Super. Ct. 1999) (describing the history of bellwether trials and their use in the mass tort context).

68. Frequently, the court will have a spreadsheet comparing and grouping plaintiffs by various categories—for example, injuries claimed and location of damage. This allows a quick and easy search for commonality and is a tool utilized for the selection of bellwether trials.

69. Alexandra D. Lahav, *Bellwether Trials*, 76 GEO. WASH. L. REV. 576, 581 (2007) (citing Richard O. Faulk, Robert E. Meadows & Kevin L. Colbert, *Building a Better Mousetrap? A New Approach to Trying Mass Tort Cases*, 29 TEX. TECH L. REV. 779, 791–92 (1998)). See Alexandra D. Lahav, *Due Process and the Future of Class Actions*, 44 LOY. U. CHI. L.J. 545, 556 (2012) (discussing equality under the law as a due process element grounded in the notion of “like cases ought to be treated alike”).

2012] *Complex Litigation in N.J. and Federal Courts* 575

settlement. For example, if the parties and counsel are in the midst of successful settlement discussions, a bellwether trial that results in a verdict outside the range of settlement—i.e., an outlier—may empower a party to go forth with the litigation and cause negotiations to break down.

Lastly, although not a case management technique per se, state and federal court judges must seek to cooperate with one another where there are related cases pending in federal MDLs and state courts.<sup>70</sup> As mass torts in New Jersey often have related matters pending in federal courts (in the form of MDLs or individual plaintiffs who have removed their case to federal court), one of the most important functions for a mass tort judge in state court is coordinating with federal courts. It is imperative for judges in state and federal courts to keep in close contact and stay abreast of developments in their respective cases.<sup>71</sup> This mutual relationship can be accomplished through formal procedures (e.g., CMCs), informal status updates from liaison counsel, or from federal judges themselves. Doing so helps ensure consistent results across the inventory of cases, avoids duplicative litigation, and allows for more efficient handling of matters in all court systems.

#### CONCLUSION

Since 2003, following the New Jersey Supreme Court's promulgation of Rule 4:38A, New Jersey's mass tort designation process has become more transparent, allowing for more orderly and predictable handling of these cases in state courts. However, following the U.S. Supreme Court's decisions in *Dukes* and *Concepcion*, there has been much speculation and discussion about the future of, and alternatives to, class

---

70. See NEW JERSEY MASS TORT (NON-ASBESTOS) RESOURCE BOOK, *supra* note 50 (advising that, at the outset of the litigation, the mass tort judge should craft a litigation plan, taking into consideration the nature of the litigation, the number of similar cases outside the court's jurisdiction, and whether a multidistrict case is pending in the federal courts). See also MANUAL FOR COMPLEX LITIGATION (FOURTH) §§ 13.1–13.21 (2009) (endorsing the use of coordinated state-federal proceedings wherever possible).

71. See, e.g., Case Management Order No. 28 at 2, *In re Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Prods. Liab. Litig.* (E.D. Ill. Feb. 28, 2011) (MDL No. 2100 3-09-md-02100-DRH-PMF) (adopting deposition protocol to be used in all MDL and state court cases, coordinating with state court judges to enter identical deposition protocol orders in California, New Jersey, and Pennsylvania; and specifically noting that “[d]isputes relating to depositions shall be resolved jointly by the Courts, wherever possible”); *In re DePuy ASR™ Hip Implants*, No. BER-L-3971-11, slip op. at 3–5 (N.J. Super. Ct. Oct. 18, 2011) (adopting joint state-MDL document production protocol). *But see In re NuvaRing Litig.*, Docket No. BER-L-3081-09 (N.J. Sup. Ct. Law Div.) (issuing an order and decision on October 22, 2012, denying defendants' request to keep certain document under seal, following the MDL's order on September 5, 2012, granting in part defendants' motion for same, the MDL has since unsealed the documents at issue, consistent with the MCL order).

actions and complex litigation.<sup>72</sup> Similar discussions have arisen following the New Jersey Appellate Division decision in *NAACP v. Foulke Management*.<sup>73</sup>

With the recently tightened class action certification standards imposed on plaintiffs by the Supreme Court, and defendants' ability to opt out of class-wide arbitration and litigation clauses, jurists are likely to see a greater number of alternatives to traditional class action lawsuits, in the form of MDL/mass tort applications, motions for consolidation pursuant to Rule 4:38, or the consolidation of a small number of related cases within the same jurisdiction before a single judge.<sup>74</sup> No matter the form, however, aggregate and complex litigation will always remain an important procedural device in civil litigation.

---

72. See, e.g., Catherine Fisk & Erwin Chemerinsky, *The Failing Faith in Class Actions: Wal-Mart v. Dukes and AT&T Mobility v. Concepcion*, 7 DUKE J. CONST. LAW & PUB. POL'Y 73, 97 (2011) ("The practical effect of these rulings is to protect corporations from class actions in both the employment and consumer contexts."); Suzette M. Malveaux, *How Goliath Won: The Future Implications of Dukes v. Wal-Mart*, 106 NW. U. L. REV. COLLOQUY 34, 52 (2011) (opining that "*Dukes* has redefined the class certification requirements for Title VII cases in ways that jeopardize potentially meritorious challenges to systematic employment discrimination" and noting that "it is clear that *Dukes* has tipped the balance in favor of powerful employers over everyday workers"); Julie Slater, *Reaping the Benefits of Class Certification: How and When Should "Significant Proof" Be Required Post-Dukes?*, 2011 BYU L. REV. 1259, 1291 (advocating for greater clarity of the "significant proof" standard and for its application "to other types of cases outside the employment discrimination context that, like *Dukes*, involve complex claims and a diverse class").

73. 24 A.3d 777 (N.J. Super. Ct. App. Div. 2011). In *Foulke*, the Appellate Division upheld the trial court's specific ruling that the class action waiver provisions in the contract documents should not be invalidated on public policy grounds, a conclusion that is consistent with the U.S. Supreme Court's decision in *Concepcion*.

74. See, e.g., *Hoffman v. Asseenontv.com, Inc.*, 962 A.2d 532 (N.J. Super. Ct. App. Div. 2009); *Hoffman v. Hampshire Labs, Inc.*, 963 A.2d 849 (N.J. Super. Ct. App. Div. 2009) (having filed 71 class action lawsuits in Bergen County over an 18-month period, the plaintiff alleged a violation of the Consumer Fraud Act, these lawsuits were never formally consolidated, however, but were assigned to one judge for pre-trial case management by directive of the Assignment Judge). For further information on the *Hoffman* cases, see Henry Gottlieb, Charles Toutant & Michael Booth, *Hoffman Unchained*, N.J. L.J. (Jan. 30, 2009); Charles Toutant, *Frequent Flier's Claim of False Advertising on Internet Dismissed*, N.J. L.J. (Jan. 12, 2009).

**BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION**

**IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS  
LIABILITY LITIGATION**

**MDL No. 2750**

**PROOF OF SERVICE**

This is to certify that pursuant to Panel Rule 4.1, a true and correct copy of the foregoing was served on October 12, 2016 on the following via the CM/ECF system, via regular mail, or via electronic mail:

**PLAINTIFF COUNSEL AND CO-COUNSEL**

Timothy J Becker  
Rolf Fiebiger  
**Johnson Becker PLLC**  
444 Cedar St., Suite 1800  
Saint Paul, MN 55101  
(612) 436-1800  
Fax: (612) 436-1801  
tbecker@johnsonbecker.com  
rfiebiger@johnsonbecker.com

**Counsel for Plaintiff**

Case No. 0:16-cv-03035-PJS-TNL: Penny Schroeder vs. Janssen Pharmaceuticals, Inc. f/k/a Janssen Pharmaceutica Inc. f/k/a Ortho-McNeil-Janssen Pharmaceuticals, Inc.; In the United States District Court for the District of Minnesota.

Case No. 1:16-cv-08838: Joy Davis vs. Janssen Pharmaceuticals, Inc. f/k/a Janssen Pharmaceutica Inc. f/k/a Ortho-McNeil-Janssen Pharmaceuticals, Inc.; In the United States District Court for the Northern District of Illinois.

Michael A. London  
Rebecca G. Newman  
**Douglas & London, PC**  
59 Maiden Lane, 6th Floor  
New York, NY 10038  
(212) 566-7500  
Fax: (212) 566-7501  
mlondon@douglasandlondon.com  
rnewman@douglasandlondon.com

**Counsel for Plaintiff**

Case No. 3:15-cv-08070-BRM-LHG: Maria Puente and Carlos Puente vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05479-BRM-LHG: Arshak Sarkisyan and Amalya Bagdasaryan vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 1:16-cv-02467-LDH-VMS: Elizabeth Sanders vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Eastern District of New York.

Donald A. Ecklund  
James E. Cecchi  
**Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.**  
5 Becker Farm Road  
Roseland, NJ 07068  
(973) 994-1700  
Fax: (973) 994-1744  
decklund@carellabyrne.com  
jcecchi@carellabyrne.com

**Counsel for Plaintiff**

Case No. 3:16-cv-01931-BRM-LHG: Kathy Seifried vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-03114-BRM-LHG; Judy Thompson vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Dae Yeol Lee  
Melissa Mendoza  
**Bernstein Liebhard LLP**  
10 East 40th Street, 28th Floor  
New York, NY 10016  
(212) 779-1414  
dlee@bernlieb.com  
mmendoza@bernlieb.com

Christopher Michael Placitella  
**Cohen, Placitella & Roth, PC**  
127 Maple Avenue  
Red Bank, NJ 07701  
(732) 747-9003  
Fax: (732) 747-9004  
cplacitella@cprlaw.com

Nicholas Rocco Farnolo  
**Napoli Shkolnik**  
400 Broadhollow Road, Suite 305  
Melville, NY 11747  
(212) 397-1000  
nfarnolo@napolilaw.com

Behram V. Parekh  
Michael Louis Kelly  
Ruth Rizkalla  
**Kirtland & Packard LLP**  
2041 Rosecrans Avenue, Third Floor  
El Segundo, California 90245  
(310) 536-1000  
Fax: (310) 536-1001  
mlk@kirtlandpackard.com  
bvp@kirtlandpackard.com  
rr@kirtlandpackard.com

Michael B. Lynch  
Amy E. German  
**The Michael Brady Lynch Firm**  
127 West Fairbanks Ave., Suite 528  
Winter Park, FL 32789  
(877) 513-9517  
Fax: (321) 972-3568  
michael@mblynchfirm.com  
amy@mblynchfirm.com

**Counsel for Plaintiff**

Case No. 3:16-cv-02361-BRM-LHG: Rose Garcia vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

**Counsel for Plaintiff**

Case No. 3:16-cv-02386-BRM-LHG: Earl Milburn, as next friend and on behalf of, Lou Milburn, Deceased vs. Janssen Research & Development LLC f/k/a Johnson and Johnson Pharmaceutical Research and Development LLC, et al.; In the United States District Court for the District of New Jersey.

**Counsel for Plaintiff**

Case No. 3:16-cv-05383-BRM-LHG: Evelyn Johnston vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05388-BRM-LHG: Joan Mullin vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05394-BRM-LHG: Stephanie Erway vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

**Counsel for Plaintiff**

Case No. 2:15-cv-02217-KJM-EFB: Jennifer Anzo vs. Janssen Research & Development, LLC, et al.; In the United States District Court for the Eastern District of California.

**Counsel for Plaintiff**

Case No. 2:15-cv-02217-KJM-EFB. Jennifer Anzo w. Janssen Research & Development, LLC, et a I.; In the United States District Court for the Eastern District of California.

Jennifer Mae Hoekstra  
Richard J. Arsenault  
**Neblett, Beard & Arsenault**  
2220 Bonaventure Ct.  
Alexandria, LA 71301  
(318) 487-9874  
rarsenault@nbalawfirm.com  
jhoekstra@nbalawfirm.com

Morris Bart, III  
**Morris Bart, LLC (New Orleans)**  
909 Poydras St. Suite 2000  
New Orleans, LA 70112-4000  
(504) 525-8000  
(504) 599-3385  
Fax: (504) 599-3380  
morrisbart@morrisbart.com

Leonard A. Davis  
**Herman, Herman & Katz, LLC**  
820 O'Keefe Avenue  
New Orleans, LA 70113  
(504) 581-4892  
ldavis@hhklawfirm.com

Waldon Michael Hingle  
Bryan August Pfleeger  
Grant Wood  
Julie Marie Jochum  
**Michael Hingle & Associates, Inc.**  
**(Slidell)**  
220 Gause Blvd., Suite 200  
P. O. Box 1129  
Slidell, LA 70459  
(985) 685-6800  
Fax: (985) 646-1471  
servewmh@hinglelaw.com  
bryan@hinglelaw.com  
grant@hinglelaw.com  
julie@hinglelaw.com

Anthony David Irpino  
John Benjamin Avin  
**Irpino Law Firm**  
2216 Magazine Street  
New Orleans, LA 70130  
(504) 525-1500  
Fax: (504) 525-1501  
airpino@irpinolaw.com  
bavin@irpinolaw.com

**Counsel for Plaintiff**

Case No. 2:15-cv-04591-MLCF-MBN: Gloria Guidry vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Eastern District of Louisiana.

**Counsel for Plaintiff**

Case No. 2:15-cv-04591-MLCF-MBN: Gloria Guidry vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Eastern District of Louisiana.

**Counsel for Plaintiff**

Case No. 2:16-cv-01189-EEF-MBN: Charles Maddox vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Eastern District of Louisiana.

**Counsel for Plaintiff**

Case No. 2:16-cv-02329-EEF-JCW: David Lessard vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Eastern District of Louisiana.

**Counsel for Plaintiff**

Case No. 3:16-cv-00319-SDD-EWD: Cassandra Jackson, Toni E. Jones, Kimberly Payne, Blaine Jackson, and Russell Jones, individually and on behalf of their deceased mother, Ida Mae Jones Jackson vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Middle District of Louisiana.



Adam A. Edwards  
Justin G. Day  
Mark E. Silvey  
**Greg Coleman Law PC**  
First Tennessee Plaza  
800 South Gay Street, Suite 1100  
Knoxville, TN 37929  
(865) 237-0080  
Fax: (865) 522-0049  
mark@gregcolemanlaw.com

Peter J. Flowers  
**Meyers & Flowers, LLC**  
3 North Second Street, Suite 300  
St. Charles, IL 60174  
(630) 232-6333  
Fax: (630) 845-8982  
pjf@meyersflowers.com

Andrew D. Schlichter  
Roger C. Denton  
Tara A. Rocque  
**Schlichter, Bogard et al. - St. Louis**  
100 South Fourth Street, Suite 650  
St. Louis, MO 63102  
(314) 621-6115  
Fax: (314) 621-7151  
aschlichter@uselaws.com  
rdenton@uselaws.com  
trocque@uselaws.com

Timothy M. O'Brien  
Travis P. Lepicier  
**Levin Papantonio Thomas Mitchell  
Rafferty & Proctor PA**  
316 South Baylen Street, Suite 600  
Pensacola, FL 32502  
(850) 435-7000  
Fax: (850) 436-6084  
tobrien@levinlaw.com  
depicier@levinlaw.com

**Counsel for Plaintiff**

Case No. 4:15-cv-00204-HLM: Paula Brazil vs. Janssen Research & Development LLC f/k/a Johnson and Johnson Pharmaceutical Research and Development LLC, et al.; In the United States District Court for the Northern District of Georgia.

**Counsel for Plaintiff**

Case No. 1:16-cv-08838: Joy Davis vs. Janssen Pharmaceuticals, Inc. f/k/a Janssen Pharmaceutica Inc. f/k/a Ortho-McNeil-Janssen Pharmaceuticals, Inc.; In the United States District Court for the Northern District of Illinois.

**Counsel for Plaintiff**

Case No. 3:15-cv-01180-SMY-DGW: Gene Schurman vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Southern District of Illinois.

Case No. 3:15-cv-01195-SMY-DGW: Anthony Allen vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Southern District of Illinois.

Case No. 3:15-cv-01196-SMY-DGW: William Counts vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Southern District of Illinois.

Case No. 3:16-cv-00557-SMY-DGW: Brenda Freeman, et al. vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Southern District of Illinois.

**Counsel for Plaintiff**

Case No. 3:15-cv-01195-SMY-DGW: Anthony Allen vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Southern District of Illinois.

Case No. 3:15-cv-01196-SMY-DGW: William Counts vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Southern District of Illinois.

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Western District of Kentucky.

Alex C. Davis  
Jasper D. Ward  
**Jones Ward PLC**  
312 S. Fourth Street, 6th Floor  
Louisville, KY 40202  
(502) 882-6000  
Fax: (502) 587-2007  
alex@jonesward.com  
jasper@jonesward.com

Justin R. Kaufman  
**Heard Robins Cloud, LLP**  
505 Cerrillos Rd., Suite A209  
Santa Fe, NM 87501  
(505) 986-0600  
Fax: (505) 986-0632  
jkaufman@heardrobins.com

Ronald E. Johnson, Jr.  
**Schachter Hendy & Johnson, PSC**  
909 Wright's Summit Parkway, Suite 210  
Ft. Wright, KY 41011  
(859) 578-4444  
Fax: (859) 578-4440  
rjohnson@pschachter.com

Alva A. Hollon  
**Sams & Hollon, PA**  
9424 Baymeadows Road, Suite 160  
Jacksonville, FL 32257  
(904) 737-1995  
Fax: (904) 737-3838  
hollonlaw@bellsouth.net

John Oaks Hollon  
Maxwell D. Smith  
**Ward Hocker & Thornton, PLLC -  
Lexington**  
333 W. Vine Street, Suite 1100  
Lexington, KY 40507  
(859) 422-6000  
Fax: (859) 422-6001  
John.hollon@whtlaw.com  
max.smith@whtlaw.com

Lionel H Sutton, III  
**Sutton Law Firm**  
935 Gravier St. Ste. 1910  
New Orleans, LA 70112  
(504) 592-3230  
Fax: (504) 585-1789  
lhs3law@hotmail.com

**Counsel for Plaintiff**

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Western District of Kentucky.

**Counsel for Plaintiff**

Case No. 3:16-cv-00107-JHM-DW: Rose Ann Adye vs. Janssen Research & Development LLC f/k/a Johnson & Johnson Pharmaceutical Research and Development LLC et al.; In the United States District Court for the Western District of Kentucky.

**Counsel for Plaintiff**

Case No. 3:16-cv-00107-JHM-DW: Rose Ann Adye vs. Janssen Research & Development LLC f/k/a Johnson & Johnson Pharmaceutical Research and Development LLC et al.; In the United States District Court for the Western District of Kentucky.

**Counsel for Plaintiff**

Case No. 3:16-cv-00330-DJH: Eric Adkins vs. Janssen Research & Development, LLC, et al.; In the United States District Court for the Western District of Kentucky.

Case No. 3:16-cv-00486-DJH: Rickie Woodward vs. Janssen Research & Development, LLC, et al.; In the United States District Court for the Western District of Kentucky.

**Counsel for Plaintiff**

Case No. 3:16-cv-00330-DJH: Eric Adkins vs. Janssen Research & Development, LLC, et al.; In the United States District Court for the Western District of Kentucky.

Case No. 3:16-cv-00486-DJH: Rickie Woodward vs. Janssen Research & Development, LLC, et al.; In the United States District Court for the Western District of Kentucky.

**Counsel for Plaintiff**

Case No. 5:16-cv-00666-SMH-KLH: Amber Rutland vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Western District of Louisiana.

Case No. 5:16-cv-00664-SMH-MLH: Ira Marshall Jr. vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Western District of Louisiana.

P. Gregory Haddad  
**Bailey & Glasser**  
6 Canyon Rd Ste. 200  
Morgantown, WV 26508  
(304) 594-0087  
Fax: (304) 594-9709  
ghaddad@baileyglasser.com

Christopher A. Seeger  
**Seeger Weiss LLP**  
77 Water St. 26th Floor  
New York, NY 10005  
(212) 584-0700  
Fax: (212) 584-0799  
cseeger@seegerweiss.com

**Counsel for Plaintiff**

Case No. 5:16-cv-00666-SMH-KLH: Amber Rutland vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Western District of Louisiana.

**Counsel for Plaintiff**

Case No. 3:16-cv-01786-BRM-LHG: Stella S. Benjamin individually and as Administratrix of the Estate of Cornelius M. Benjamin vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-01787-BRM-LHG: Robert Partington vs. Janssen Pharmaceuticals, Inc., et al.,- In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-01897-BRM-LHG: Sherry Anders and Joseph Anders vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court or the District of New Jersey.

Case No. 3:16-cv-01898-BRM-LHG: Shelley Swinney and William Swinney vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-01931-BRM-LHG: Kathy Seifried vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-02048-BRM-LHG: Brittany Bowling and Ricky Bowling vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-02050-BRM-LHG: Karen Robertson and Samuel Robertson vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-02278-BRM-LHG: Greg Humphries and Yvette Humphries vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-02938-BRM-LHG: Mark Kuno vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-03114-BRM-LHG: Judy Thompson vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey

Case No. 3:16-cv-03362-BRM-LHG: Brian Henderson and Tara Henderson vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-04024-BRM-LHG: Laura Waddle vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-04136-BRM-LHG: Nathan Warren vs. Janssen Pharmaceuticals,

Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-04484-BRM-LHG: Sheryl Desalis vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-04485-BRM-LHG: Carolyn Forehand vs. Janssen Pharmaceuticals, Mc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-04486-BRM-LHG: Keisha Jackson vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-04489-BRM-LHG: Teresa Rogers vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-04490-BRM-LHG: Scot Sutherland vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05316-BRM-LHG: Wayne Lemke vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05478-BRM-LHG: Crystal Ervin and Lee Ervin vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05645-BRM-LHG: Judith Buchanan vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05649-BRM-LHG: Victor Felix and Dawn Felix vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05674-BRM-LHG; Angela Hudson vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05675-BRM-LHG: Bonnie Jayjohn and Donald Jayjohn vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05676-BRM-LHG: William Kemp and Teresa Kemp vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05677-BRM-LHG: Iliana Luna and Gamaliel Bernabe vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05681-BRM-LHG: Earl Poole vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05682-BRM-LHG: Susan Stringer and Charles Stringer vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05683-BRM-LHG: Carole Williams vs. Janssen

Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey

Joseph G. Dell  
Jon-Paul Gabrielle  
**Dell & Dean, PLLC**  
1225 Franklin Avenue, Suite 450  
Garden City, NY 11530  
(516) 880-9700  
Fax: (516) 880-9707  
jdell@d2triallaw.com  
jgabriele@d2triallaw.com

Richard A. Wright  
**Cory Watson, P.C.**  
2131 Magnolia Avenue, Ste. 200  
Birmingham, AL 35205  
(205) 328-2200  
Fax: (205) 324-7896  
rwright@corywatson.com

Edward A. Wallace, Esq.  
Timothy E. Jackson, Esq.  
**Wexler Wallace**  
55 W. Monroe St. Ste. 3300  
Chicago, IL 60603  
(312) 346-2222  
Fax: 312-346-0022  
eaw@wexlerwallace.com  
tej@wexlerwallace.com

#### **DEFENSE COUNSEL**

Carol D. Browning  
Whitney Frazier Watt  
**Stites & Harbison, PLLC - Louisville**  
400 W. Market Street, Suite 1800  
Louisville, KY 40202-3352  
(502) 587-3400  
Fax: (502) 779-8232  
cbrowning@stites.com  
wwatt@stites.com

Ana C. Reyes  
Dane H. Butswinkas  
Stephen D. Raber  
**Williams & Connolly LLP**  
725 Twelfth Street, NW Washington, DC  
20005  
(202) 434-5000  
Fax: (202) 434-5029  
dbutswinkas@wc.com  
sraber@wc.com  
areyes@wc.com

#### **Counsel for Plaintiff**

Case No. 3:16-cv-06046-BRM-LHG: Bruce Green v. Janssen Pharmaceuticals, Inc. et al.; In the United States District Court for the District of New Jersey.

#### **Counsel for Plaintiff**

Case No. 3:16-cv-00065-HRW: Scot and Brenda Moore vs. Janssen Research & Development LLC et al.; In the United States District Court for the Eastern District of Kentucky.

#### **Counsel for Plaintiff**

Case No. 3:16-cv-00065-HRW: Scot and Brenda Moore vs. Janssen Research & Development LLC et al.; In the United States District Court for the Eastern District of Kentucky.

#### **Counsel for Defendants:**

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Western District of Kentucky.

#### **Counsel for Defendants:**

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Western District of Kentucky.

**DEFENDANTS**

**Mitsubishi Tanabe Pharma Holdings America, Inc.**

525 Washington Boulevard, Suite 400  
Jersey City, NJ 07310

Case No. 3:16-cv-05383-BRM-LHG: Evelyn Johnston vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05388-BRM-LHG: Joan Mullin vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05394-BRM-LHG: Stephanie Erway vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District-Court for the District of New Jersey.

**Mitsubishi Tanabe Pharma Development America, Inc.**

525 Washington Blvd., Suite 400  
Jersey City, New Jersey 07310

Case No. 3:16-cv-05383-BRM-LHG: Evelyn Johnston vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05388-BRM-LHG: Joan Mullin vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05394-BRM-LHG: Stephanie Erway vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

**Tanabe Research Laboratories U.S.A., Inc.**

4540 Towne Centre Court  
San Diego, California 92121

Case No. 3:16-cv-05383-BRM-LHG: Evelyn Johnston vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05388-BRM-LHG: Joan Mullin vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

Case No. 3:16-cv-05394-BRM-LHG: Stephanie Erway vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the District of New Jersey.

**Bristol-Myers Squibb Company**

345 Park Avenue  
New York, New York 10154

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Western District of Kentucky.

c/o The Corporation Trust Company  
Corp. Trust Center  
1209 Orange St.  
Wilmington, DE 19801

**Astrazeneca PLC**

2 Kingdom Street  
London, England, W2 6BD

Case No. 3:15 cv-00894-JHM-CHL; Anna House vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Western District of Kentucky.

**Astrazeneca LP**

c/o The Corporation Trust Company  
Corp. Trust Center  
1209 Orange St.  
Wilmington, DE 19801

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Western District of Kentucky.

**Astrazeneca Pharmaceuticals LP**  
c/o The Corporation Trust Company  
Corp. Trust Center  
1209 Orange St.  
Wilmington, DE 19801

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs. Janssen Pharmaceuticals, Inc., et al; In the United States District Court for the Western District of Kentucky.

**Astrazeneca AB**  
Karlebyhus, Astraallen  
15185 Sodertalje  
Sweden

Case No. 3:15-cv-00894-JHM-CHL: Anna House vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the Western District of Kentucky.

Dated: October 12, 2016

TUCKER ELLIS LLP

/s/ John Q. Lewis

---

John Q. Lewis

Attorneys for Defendants Janssen Pharmaceuticals, Inc., Janssen Research & Development, LLC, Janssen Ortho, LLC, Johnson & Johnson, and Mitsubishi Tanabe Pharma Corporation